Prosonix Elects Dr Ken Cunningham as Non-executive Chairman - Gilde Healthcare

Prosonix Elects Dr Ken Cunningham as Non-executive Chairman

5 December 2012

Prosonix (Oxford, UK), a speciality pharmaceutical company developing a portfolio of inhaled respiratory medicines enabled by its unique particle engineering technology, announces the election of Dr Ken Cunningham as Non-executive Chairman. He replaces Dr Jim Philips, who has been Chairman of the Company since 2007.

Dr Cunningham was elected to the Board of Prosonix as a Non-executive Director in September 2011, and is also Chair of Prosonix’s Scientific Advisory Board. He has over 20 years’ experience in the pharmaceutical industry with a strong focus in recent years on respiratory drug development and drug delivery. He is Chairman of PolyTherics Ltd and until August 2010 was CEO of Skyepharma plc. Before that he was Chief Executive Officer of Arakis Ltd, Vice-President European Affairs at Alza Corporation and Vice-President Clinical Development at Sequus Inc. He holds a medical degree from St Mary’s, Imperial College, London University.

Dr Ken Cunningham said:

“Over recent years, Prosonix’s particle engineering technology has repeatedly demonstrated its exciting potential for optimising many of the respiratory medicines currently used in the treatment of asthma and COPD. During this period, the Company has made a successful transition from applying its technology to third party compounds to using it to build its own pipeline of directly substitutable generic and proprietary inhaled drugs based on improved versions of known drugs in simple, cost effective and already approved devices. I would like to take this opportunity, on behalf of the Prosonix Board, to thank Dr Phillips for his important contribution as Chairman during this period of transformation. I am very pleased to continue his work and help Prosonix deliver its corporate and clinical strategy, which is focused on building further value from the Company’s portfolio of inhaled drug candidates.”

Dr Jim Phillips said:

“After five years chairing Prosonix and helping shape it into the inhalation product-focused company it is today, I am delighted to hand over Chairmanship to Dr Ken Cunningham to bring his respiratory experience to bear towards the Company’s future success.”

Gilde Healthcare portfolio company Nyxoah announces CE-mark approval to treat complete concentric collapse (CCC) patients

Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that DEKRA Notified Body has approved...
5 October 2021

Gilde Healthcare portfolio company Noema Pharma appoints Jeffrey Jonas as Independent Chairman of the Board of Directors

Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system (CNS) diseases, today announces the appointment of Jeffrey Jonas MD as Chairman of the Board of Directors. Dr. Jonas is a neuropsychiatry expert...
4 October 2021

Gilde Healthcare company Acacia Pharma announces marketing authorization application for BARHEMSYS® in Europe

Acacia Pharma (EURONEXT: ACPH), a commercial stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures, or cancer chemotherapy, announces...
29 September 2021